Strategies to inhibit the spread of HIV infection consist of moter. This fusion mutant was also examined for its a number of specific molecular approaches. Since viral capacity to block both Tat-mediated transactivation and production is dependent upon Tat-mediated transactivation HIV replication. We show that three mutants Tat⌬53, of the HIV promoter through the Tat activating region Tat⌬58 and Tat⌬53/Eng result in a transdominant pheno-(TAR), tat antisense RNA, anti-tat ribozymes, TAR decoys type inhibiting wild-type Tat-mediated transactivation, and and dominant negative Tat mutant proteins have been sugthat the inhibiting potential is increased by the presence of gested as therapeutic inhibitors. We produced and tested the entire basic domain or the fusion of a repressor several Tat mutant proteins, including a newly generated domain. However, only the transdominant mutants Tat⌬58 form Tat⌬58, for the ability to inhibit Tat-mediated transand Tat⌬53/Eng significantly inhibit HIV-1 replication after activation and HIV production. In addition, we generated a infection of transfected T cell lines. These results demonnew Tat fusion mutant between a C-terminus truncated strate the potent inhibiting activity of Tat mutants on HIV form of Tat (Tat⌬53) and the Drosophila Engrailed (Eng) replication, and suggest a synergistic effect of Tat transtranscription repressor domain to test the hypothesis that dominant mutant fusion with the Drosophila Engrailed trantranscriptional repression can be targeted to the HIV proscription repressor domain.
Introduction
One of the many molecular strategies currently being examined to inhibit the spread of HIV infection consists of gene-based therapy utilizing genes encoding for HIV mutant regulatory or structural proteins known as transdominant or dominant negative mutant proteins. Transdominant proteins have been described for a variety of HIV-1 proteins including Tat, 1-3 Rev 4-6 and Gag. 7 These mutant proteins are defective in their normal function and are able to compete with the corresponding wildtype protein to inhibit its activity. As it has been previously shown, one excellent target for transdominant inhibition is the regulatory protein Tat (reviewed in Ref. 8) .
Tat is a potent transactivator of HIV long terminal repeat (LTR)-directed gene expression. It consists of 86 amino acids (aa) and can be taken up by cells in tissue culture. 8 The first 72 amino acids encoded by exon 1 of tat are fully active in transactivation of the HIV LTR. The Tat protein contains at least two domains that are functionally important in HIV transactivation and replication: an activation domain (aa 1-48) which promotes trans-activation of transcription, and an arginine-rich basic domain (aa 49-57) which mediates Tat binding to Tat transactivation element (TAR) RNA and also functions in nuclear localization (reviewed in Ref. 8) . Although not defined by specific domains, the glutamine-rich region between residues 58 and 72 seems to augment the action of Tat since a synthetic peptide containing residues 1-58 has been shown to have 5-10% the activity of the 1-86 or 1-72 Tat protein. 9 The carboxy-terminal amino acids of Tat (residues 72-86) do not appear essential for transactivation but they contain the conserved RGD motif that mediates binding of Tat to integrins allowing exogenous Tat to be taken up by cells. 8 Previously, it has been shown that mutations of HIV-1 or HIV-2 Tat protein consisting of substitutions in the transactivation domain, Tat22, Tat37, Tat22/37, 10 Tat41-ala, Tat47ala 2 and in the basic domain Tat55/58, Tat54/57 Tat52/57, 3 Tat50/57, 11 or carboxy-terminus truncations which partially remove the basic domain, Tat⌬53, 1 result in proteins defective in transactivating HIV gene expression. These mutant proteins act as transdominant proteins which inhibit wild-type Tat-mediated transactivation. In addition, mutant proteins with amino acid substitutions between aa 52 and 57 (Tat 52/57) 12 or between aa 50 and 57 (Tat 50/57), 11 and substitution at position 22 (Tat22) 10 have been shown to inhibit HIV replication. However, no inhibition of HIV replication could be observed with the truncated mutant Tat⌬53. 13 To explore further the potential of Tat mutant proteins in inhibiting the spread of HIV infection for possible clinical applications, we generated several transdominant mutants of Tat: substitutions mutants, carboxy-terminus truncated mutants including a new form Tat⌬58 harboring the entire basic domain, and a Tat mutant (Tat⌬53) coupled to the repressor domain of a known transcription factor. The alanine-rich domain of the Drosophila Engrailed (Eng) transcription factor has been shown to act as a strong active repressor of transcription by competition with the TATA box-binding protein transcription factor IID (TFIID).
14 Additionally, the fusion of the Drosophila Engrailed transcription repressor domain with the Myb DNA-binding domain acts as a potent competitive inhibitor of c-Myb in transgenic animals and perturbs thymic development. 15 Moreover, recent evidence suggests that a chimeric protein with a virus-specific DNA or RNA-binding domain and a strong transcriptional repressor function may interfere with the expression of viral gene products in infected cells. [16] [17] [18] Indeed, Tat mutants fused to the Krü ppel-associated box repressor (KRAB) showed an enhanced inhibiting activity of Tatmediated transactivation. 19 The object of the present study was to transiently and stably express the transdominant mutants in reporter cells and human T lymphoid cell lines, respectively, in order to interfere with HIV LTR-driven gene expression and HIV infection. We show here that truncated mutants Tat⌬53 and Tat⌬58 inhibit wild-type Tat-mediated transactivation and that this inhibiting activity is enhanced with the fusion mutant between Tat⌬53 and the Engrailed repressor domain (Tat⌬53/Eng). Tat⌬58 and Tat⌬53/Eng mutants also effectively inhibit HIV-1 replication in vitro, while Tat⌬53 fails to show any effect on HIV-1 infection. These results suggest the potential use of transdominant mutant protein and the Engrailed repressor domains of transcription factors for gene therapy against HIV-1 infection.
Results

Differential transactivation of HIV LTR by Tat molecules
Several HIV-1 Tat mutants were generated by PCR amplification using specific oligonucleotides as described in Materials and methods (Figure 1a ). These substitutions and deletions were chosen because a transdominant phenotype has been previously described for a Tat protein containing an alanine residue substituting for lysine 41 and tyrosine 47, and for peptides spanning aa 37-72. 2 Pearson et al 1 described a different trans-dominant inhibitory Tat mutant truncated by a premature stop codon at aa 54. In order to make an improved transdominant mutant, we have generated a new truncated form Tat⌬58 so as to include all the activation domain and the arginine-rich TAR-binding domain. In addition to expecting these structural forms of Tat to act as transdominant inhibitors, we tested the hypothesis that the Drosophila Engrailed (Eng) transcription repressor domain would result in further HIV inhibition. Thus, a Tat⌬53/Eng fusion construct was generated. Each Tat mutant was inserted in the SV40 (pSG5) and human CD2 (pCD2-puro) expression cassettes (Figure 1b) for efficient transcription in human cell lines. Before testing whether the Tat mutants could inhibit wild-type Tat-mediated trans- activation of the HIV promoter, we tested if the mutants themselves were defective in the transactivation of the HIV promoter. Hela cells containing the human growth hormone (hGH) gene under the control of the HIV LTR (LTRhGH) 20 were utilized as reporter cells and were transiently transfected with 0.5 g of wild-type (wt) or mutant tat DNAs (Figure 2a) . At 3 days after transfection, supernatants were tested for the presence of hGH protein by RIA. As shown in Figure 3 , maximal transactivation (100%) was found with the wild-type Tat (Tat-wt), giving the expected 10-to 20-fold increase in expression over the basal levels of LTR-directed expression (defined as 0% transactivation). Similarly, a high level of transactivation (Ͼ90%) was also obtained with the Tat47ala mutant. However, only a low level of transactivation was observed in the presence of Tat41ala, Tat⌬53 and Tat⌬58, giving 7, 7.5% and 7.8% transactivation, respectively. Transactivation ability was completely abolished with the Tat⌬53/Eng mutant as only the basal levels of hGH reporter gene were found ( Figure 3 ). As controls, the expression vector containing each of the tat mutant genes in the antisense orientation did not induce transactivated hGH expression in any of the transfection experiments performed (data not shown). These results demonstrate that several mutations of the tat gene abolish or substantially decrease the transactivation function of this regulatory molecule.
Potent inhibition of Tat-mediated transactivation by the truncated Tat mutants
To test for the inhibition of Tat-mediated transactivation by the nontransactivating Tat mutants we performed cotransfection experiments with wild-type tat and tat mutant DNAs in Hela reporter cells (Figure 2b ). Cotransfection of pSG5Tat-wt (0.5 g) in combination with each of the pSG5tat mutant plasmid DNAs was carried out with a specific wild-type:mutant ratio of 1:5. As controls, cotransfection experiments were performed with antisense constructs of tat mutant sequences ( Figure 4a ). All nontransactivating Tat mutants inhibited the wild-type 
The level of transactivation was assessed by analysis of hGH in culture supernatant 72 h after transfection. Maximal transactivation obtained with wild-type Tat was defined as 100% transactivation. The basal level of HIVLTRhGH expression was defined as 0% transactivation. Transfection efficiency was monitored using a pCMVLacZ plasmid vector and values were normalized after spectrophotometric substrate detection. Controls were nontransfected cells and cells transfected only with pCMVLacZ, and showed no transactivation (data not shown). Data are expressed as means ± standard deviation of at least three separate experiments.
transactivation of the HIV LTR. The most potent inhibition of Tat-mediated transactivation was obtained in the presence of Tat⌬53/Eng and Tat⌬58 mutants, giving 73 and 61% inhibition, respectively, at a five-molar excess over the Tat-wt. Tat⌬53 and Tat41ala also showed inhibiting effects on Tat-mediated transactivation, giving 57 and 48% inhibition, respectively. In contrast, antisense Tat⌬53/Eng and Tat⌬58 mutants showed no inhibition of Tat-mediated transactivation, thus demonstrating the specificity of inhibition by sense mutants.
The specificity of inhibition was verified by performing the cotransfection experiments with various wt-Tat to Tat mutant ratios; 1:1, 1:2 and 1:5. Each cotransfection was performed with a total of 3 g DNA. As shown in Figure  4b , the percentage inhibition by each of the Tat mutants is decreased as less mutant DNA is cotransfected. Consistent with the previous result, Tat⌬53/Eng inhibited transactivation better than any other Tat mutant at all ratios tested. At equimolar ratios, Tat⌬53/Eng decreased the transactivation by wt-Tat to almost 50%. Tat⌬58, Tat⌬53 and Tat41ala were able to inhibit transactivation at the 1:1 ratio but much less effectively (35, 26 and 25%, respectively). Thus inhibition directly correlates with the quantity of mutant Tat DNA transfected, strongly suggesting specificity of inhibition by Tat mutants.
Expression of tat RNA in stably transfected CEM cells
The efficient but incomplete trans-negative effects of the mutant Tat on HIV LTR transactivation prompted construction of a better expression cassette for transfection and HIV infection experiments in T cell lines. The human CD2 gene control elements are known to direct T cellspecific expression to high levels due to the presence of the locus control region (LCR). LCRs have been described as elements capable of yielding position-independent and copy number-dependent expression of heterologous transgenes. 21 Thus, Tat mutant DNAs were inserted into the pCD2-puro expression plasmid (Figure 1b) containing the CD2 promoter, 3Ј untranslated region (UTR) and locus control region (LCR). 22 CEM cells were stably transfected with each pCD2-tat mutant construct and tested for the expression of tat mutant RNA by RT-PCR. RNA was digested with RNase-free DNase to eradicate potentially contaminating DNA and reverse transcription was performed with randomized oligonucleotides. The resultant cDNA was amplified in the presence of tat-specific primers. As shown in Figure 5 , the presence of a 158-bp PCR product detected after hybridization with a tatspecific probe and common to the three Tat mutants, confirmed the expression of tat mutant RNA in CEM cells transfected with pCD2-Tat⌬53, pCD2-Tat⌬58 and pCD2-Tat⌬53/Eng. As a positive control, Jurkat/Tat cells expressing the wild-type Tat (aa 1-72) showed a high level of expression of tat RNA. No corresponding DNA product was amplified from control CEM or CEM cells transfected with the control pCD2 vector ( Figure 5 ) or from samples that were not subjected to the RT (data not shown). As internal control, the endogenous expression of human ␤-actin was determined by cDNA amplification with specific primers. All samples showed a 590-bp PCR product characteristic of ␤-actin expression ( Figure 5 ). Semiquantitative analysis of RNA expression using serial-diluted cDNA, and Phosphorimager analysis after normalisation to the ␤-actin internal control showed that Tat⌬53 and Tat⌬58 RNAs were expressed at the same level and that Tat⌬53/Eng RNA was expressed at a twofold higher level.
Inhibition of HIV-1 replication in CEM cells expressing Tat⌬58 and Tat⌬53/Eng
To determine if the CEM cell lines expressing transdominant Tat mutants inhibited HIV-1 replication, each transfectant pool (Tat⌬53, Tat⌬58 and Tat⌬53/Eng) was infected with HIV-1 and its replication compared with that of the parental untransfected control CEM cells as well as the control CEM cells transfected with the pCD2 expression cassette. Triplicate cultures of the CEM populations were infected with HIV-1 IIIB/LAI and were maintained in the absence of drug selection during the course of infection. Every 3-4 days, cell-free supernatants were tested for the presence of RT activity or p24 core protein ( Figure 6 ).
After challenge with HIV-1 at a low mutiplicity of infection (MOI 0.0001, 50 TCID 50 /ml), substantial inhibition of HIV-1 replication in Tat⌬58 transfectants was observed throughout the 23 day culture period (Figure  6a ). Only 2 ng/ml of p24 was detected at day 23, whereas p24 levels rapidly increased after day 6 for the control pCD2-transfected cells. The p24 levels of the control cells reached a concentration of 5-10 g/ml beginning at day 16. Thus, the Tat⌬58 mutant is able to inhibit HIV replication, as measured by p24 levels, by a factor of 10 000-25 000. In addition, while Tat⌬53 transfectants showed no inhibiting effects (and appeared to be potentiating infection), Tat⌬53/Eng transfectants inhibited infection during the first 16 days of culture. Approximately a 40-fold reduction of p24 production was observed at day 16 when Tat⌬53/Eng transfectants were compared with Tat⌬53 cells.
To test the efficiency of inhibition by the Tat mutants further, CEM transfectants were challenged with higher doses of HIV-1 IIIB/LAI ; MOI 0.0002 (Figure 6b ), MOI 0.001 ( Figure 6c ) and MOI 0.002 (Figure 6d ). Tat⌬58 showed the greatest inhibiting effects, as measured by RT activity at all infective doses used. At an MOI of 0.0002, a 10-to 20-fold reduction in RT activity was obtained in supernatant of Tat⌬58 cells up to day 13. A five-to 10-fold inhibition of HIV replication was also found up to day 13 at an MOI of 0.001 and up to day 7 at an MOI of 0.002, after which levels of RT approached the levels found in control pCD2-transfected cells and control parental CEM populations, respectively. Tat⌬53/Eng also showed inhibiting effects. At an MOI of 0.0002, Tat⌬53/Eng-transfected cells could inhibit RT activity by a factor of four up to day 10 as compared with control infected cells. At the higher MOI of 0.001, only a two-fold reduction in RT activity (280 c.p.m./100 l for Tat⌬53/Eng compared with 560 c.p.m./100 l for control pCD2-transfected cells) was detected at day 6. In contrast, Tat⌬53 showed no inhibiting activity at any day at an MOI of 0.001, but instead, increased HIV-1 replication substantially. Thus, when HIV infection of Tat⌬53/Eng transfectants is compared directly with Tat⌬53 cells as the control, a 13-and two-fold reduction of HIV replication is observed at day 9 and day 12, respectively, suggesting that the Engrailed repressor domain is effective in inhibiting HIV replication even at high viral doses. Taken together, these results demonstrate that both Tat⌬53/Eng and Tat⌬58 inhibit HIV-1 replication in a viral dosedependent manner.
Discussion
The use of transdominants of the HIV-1 regulatory protein Tat has been proposed as a possible therapeutic approach method for inhibition of HIV replication. In this study, we examined the ability of several Tat transdominant mutants with either amino acid substitutions in the activation domain or with C-terminus truncations to inhibit Tat-mediated transactivation or inhibition of HIV replication in human T cell lines. To increase the potential transdominant inhibitory effects further and to test the hypothesis that transcriptional repression can be targeted to the HIV promoter, we also generated and examined the inhibiting effects of a fusion mutant between a truncated Tat and the Drosophila Engrailed transcription repressor domain.
Out of the Tat mutants generated, only Tat with a lysine to alanine substitution at position 41 (Tat41ala), Tat C-terminus deletions (Tat⌬53 and Tat⌬58), and the Tat⌬53-Drosophila Engrailed repressor domain fusion (Tat⌬53/Eng), did not transactivate HIV LTR-driven gene expression. Instead, these mutants showed a strong transdominant phenotype, inhibiting wild-type Tatmediated transactivation. Inhibition was specific and dose-dependent. While two separate groups have described the transdominant phenotype of Tat41ala and Tat⌬53, 1,2 we show by direct comparison that the newly generated C-terminus deletion mutant Tat⌬58 harboring the entire TAR-binding region, and the fusion mutant Tat⌬53/Eng act as the most effective dominant negative proteins, followed by Tat⌬53 and Tat41ala. At a 1:1 wildtype to mutant ratio, Tat41ala and Tat⌬53 were able to inhibit transactivation equally by 25%, while at a 1:5 ratio, Tat⌬53 inhibits slightly better (55%) than Tat41ala (45%). In contrast, Tat⌬58 yielded a 35% (1:1 ratio) and 60% (1:5 ratio) decrease in transactivation compared with wild-type Tat. Overall, the fusion mutant Tat⌬53/Eng is the most potent inhibitor; inhibiting 70% of the wild-type Tat-mediated transactivation, Tat⌬53/Eng is 10% better than Tat⌬58 and 15% better than Tat⌬53 without the Engrailed domain.
As a more rigorous investigation of the inhibitory properties of the transdominants, the Tat⌬53 and Tat⌬58, and Tat⌬53/Eng mutants were tested for the ability to inhibit viral replication in vitro. Inhibition of HIV-1 IIIB/LAI replication was observed in CEM cells expressing Tat⌬58 in a viral dose-dependent manner. Tat⌬53/Eng also showed an inhibiting effect at low viral doses when compared with the CD2 vector control transfectants, but failed to show any protection against HIV-1 when the amount of input virus was increased, and rather than inhibiting HIV replication, Tat⌬53 potentiated viral production by at least two-fold. Thus when Tat⌬53 is used as the control, Tat⌬53/Eng inhibits HIV replication in a dose-dependent manner.
In contrast to the results of the transactivation assays, the inhibition of HIV replication was most efficient with the Tat⌬58 mutant. Tat⌬58 was able to inhibit HIV replication completely up to at least day 23 after infection at a low MOI. The lack of strong inhibition by Tat⌬53/Eng is unexpected since a two-fold higher level of tat RNA is found in the Tat⌬53/Eng than in the Tat⌬58 populations. It is possible that the intracellular localization of Tat mutants varies in transiently transfected reporter cells as compared with stable transfectants used for in vitro HIV infection. Moreover, other viral or cellular proteins present in human T cells and not in Hela reporter cells may affect Tat mutant localization and thus activity. These differences in reporter assays versus inhibition of HIV replication illustrate the necessity of testing mutants in infection scenarios.
From our results, it appears that at least a five-fold molar excess of the transdominant Tat mutant protein is necessary to markedly inhibit wild-type Tat-mediated transactivation. As judged by detection of tat-specific RNAs, not all the transfected CEM cell populations used for HIV infection experiments express high levels of the mutant tat gene. Since the cells are uncloned drug-resistant populations, some of the transfected cells (those with lower levels of tat transdominant mutant transcription) may not be protected when challenged with increasing doses of virus. As suggested by others, 11, 13 because Tat acts on the HIV-1 LTR in a positive feedback loop to increase its own expression, the amount of wild-type Tat protein synthesized during the course of infection may be sufficient to overcome the effects of the transdominant Tat mutant protein and thus avoid the complete inhibition of replication. Indeed, it has been recently reported that high levels of transdominant RevM10 protein are required to inhibit HIV-1 replication. 23 Future experiments will focus on the use of transfectant clones which may express higher levels of Tat transdominant mutant.
Considering the possible mechanisms of inhibition, it has been suggested previously that Tat⌬53 sequesters cellular factors in the cytoplasm which are necessary for efficient viral transcription. 3 Alternatively, inactive complexes are formed between wild-type and Tat⌬53. In addition to these mechanisms, our data suggest that Tat⌬58 may act by competition with the wild-type protein for binding to the TAR RNA sequence. While some or all of these mechanisms may be operating, the fusion of the Engrailed repressor domain to Tat⌬53 suggests action within the transcriptional complex itself. The Drosophila Engrailed protein has been described to compete with the TATA-box binding protein transcription factor IID (TFIID) for binding to the TATA box, 14 leading to a transcription repression mechanism. Physical interactions have also been demonstrated between Tat and the TATAbinding protein (TBP) which is part of TFIID. 24 The combination of these two mechanisms may then contribute to the enhanced inhibitory effect observed with the fusion mutant Tat⌬53/Eng; the Tat mutant sequestering cellular factors, particularly TFIID, and Engrailed blocking the access of TFIID to the TATA box. Previously, an improvement of a Tat transdominant phenotype has been described for Tat22/37 and Tat37 mutants fused to the Krü ppel-associated box repressor (KRAB). 19 Taken together, these data support the hypothesis that chimeric proteins containing a virus-specific DNA or RNA-binding domain and a strong repressor domain may interfere with the expression of viral gene products in infected cells. [16] [17] [18] Therefore, the use of the Engrailed domain to enhance the inhibitory effect of transdominant Tat mutants may represent a novel strategy for inhibiting HIV-1 infection.
Successful inhibition of HIV infection has been reported in CD4
+ cells from non-infected individuals transduced with vectors expressing Rev transdominant mutant RevM10, 6, 23 anti-tat ribozymes, tat antisense molecules and TAR RNA decoys. 25 Suppression of HIV replication and prolonged survival was also observed in CD4 + cells from HIV-positive subjects, ex vivo transduced with anti-HIV genes expressing an anti-U5 ribozyme or the RevM10 transdominant mutant. 26, 27 Hence, to analyse further the efficacy of the Tat mutants described, experiments should be carried out to determine whether Tat⌬58 and Tat⌬53/Eng are protective against different laboratory and primary isolates of HIV-1, and whether they can inhibit HIV-1 infection in primary cells. Since macrophages serve as reservoirs for HIV-1 during the asympto-matic phase of infection, Tat mutants need to be tested against macrophage-tropic HIV-1 strains, which have been shown to be the predominant type in primary isolates from HIV-infected patients. In fact, all the cells affected by HIV-1 infection, including CD4 + T lymphocytes, macrophages, dendritic cells and central nervous system (CNS) microglial cells, are derived from hematopoietic stem cells. Therefore, gene transfer into pluripotent hematopoietic stem cells would be a preferred strategy for achieving sustained immune reconstitution. 28 Recent studies have shown that the bone marrow from HIV-1-infected donors yielded CD34
+ progenitor cells of sufficient quality and quantity to be used as targets for gene therapy. 29 Thus, for combination stem cell therapy, the further development of the Tat⌬58 and Tat⌬53/Eng mutants may yield potent inhibitors against HIV-1 replication for use in clinical applications.
Materials and methods
Cells and virus CEM and Jurkat cells were grown in RPMI 1640 (GIBCO BRL, Life Technologies, Paisley, UK) containing 5% heatinactivated fetal calf serum (FCS), and supplemented in antibiotics and glutamine, at 37°C 5% CO 2 . Hela reporter cells were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL)-10% FCS supplemented in antibiotics and glutamine, at 37°C 5% CO 2 .
HIV-1 IIIB/LAI strain was kindly provided by the MRC AIDS Reagent Project. Virus stocks were prepared by infecting CEM cells. The virus titer of cell-free supernatant from infected CEM cells was determined to be 10 6 tissue culture 50% infective dose (TCID 50 ) per ml.
Generation of Tat mutants
Exon 1 of tat (wild-type Tat) was amplified by PCR from pCMVTat (provided by Dr Edward Blair, Wellcome Laboratories, Beckenham, UK), using the 5Ј primer GCT CTAGAATTCATGGAGCCAGTAGATCC containing XbaI and EcoRI sites and the 3Ј primer (5Ј → 3Ј) CGGGAT CCAGATCTTTACTGCTTTGATTAGA containing BglII and BamHI sites and a stop codon. The wt-Tat fragment was cloned into the EcoRI-BglII sites of the expression vector pSG5 (Stratagene, La Jolla, CA, USA). Tat41ala and Tat47ala fragments were generated by PCR and overlapping oligonucleotides introducing a substitution at positions 41 and 47, respectively, and cloned into the EcoRI site of pSG5 vector. Tat⌬53 was obtained using the 5Ј primer for wt-Tat and the 3Ј primers (5Ј → 3Ј) CGGGATC CAGATCTTTATCTCCGCTTCTTCCTGC containing BglII and BamHI sites, or CGGAATTCTTATCTCCGCTTC TTCCTGC containing an EcoRI site. Both 3Ј primers have been designed to introduce a stop codon at position 54. Tat⌬53 was cloned into EcoRI-BglII sites of pSG5 vector, and the EcoRI site of the human CD2 expression vector (pCD2 vector) (a gift from Dr D Kioussis, NIMR, London, UK). Tat⌬58 was amplified using the 5Ј primer above and the 3Ј primer (5Ј → 3Ј) CGGGATCCAGATCTGAAT TCTTAAGCTCTTCGTCGCTGTCT containing BamHI, BglII and EcoRI sites. Tat⌬58 was cloned into the EcoRI site of pSG5 and pCD2-puro vectors. The fusion mutant Tat⌬53/Eng was generated as follows: the Tat⌬53 fragment was obtained using the 5Ј primer above and the 3Ј primer (5Ј → 3Ј) TTTCGCGCGCCGCTTCTTCCTGC containing a BssHII site. The Engrailed (Eng) repressor domain was amplified using the 5Ј primer TTTGGCGCGCCCTGGAGGATCGCTGC containing a BssHII site and the 3Ј primer (5Ј → 3Ј) CCGGAA TTCCTAGTTCAGGTCCTCCTC containing an EcoRI site and a stop codon. The BssHII site allowed the direct inframe fusion between the two protein sequences. The Tat⌬53 and Engrailed fragments were inserted into the EcoRI site of pSG5 and pCD2-puro vectors.
Transient transfection experiments
Transient transfections were performed with the Lipofectamine reagent (Gibco BRL, Life Technologies), according to the manufacturer's instructions, using a Hela HIVLTRhGH reporter cell line containing the human growth hormone (hGH) gene under the control of the HIV LTR. 20 The level of Tat-mediated transactivation was assessed by RIA (Tandem HGH; Hybritech, Liège, Belgium) of the hGH protein in culture supernatant 72 h after transfection. Transfection efficiency was monitored using a pCMVLacZ plasmid vector and values were normalised after spectrophotometric substrate detection. 20 Electroporation of CEM cells CEM cells were washed twice with cold RPMI 1640 and resuspended at 10 7 cell/ml in cold RPMI 1640. For each sample, cells were mixed with 20-30 g of KpnI-linearized plasmid DNA and placed into disposable electroporation cuvettes (0.4 cm gap width, Bio-Rad, Richmond, CA, USA) for 10 min on ice. Electroporations were then performed with the Bio-Rad Gene Pulser at 500 F and 300 V for 20 ms. After electroporation the cells were maintained in the cuvettes for 10 min on ice and then transferred into 15 ml of RPMI 1640-15% FCS. Two days later, debris and dead cells were removed by density gradient (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) and viable cells were resuspended in RPMI 1640-15% FCS containing 0.5 g/ml puromycin (Sigma, St Louis, MO, USA).
RNA analysis
RNA samples were extracted with LiCl/Urea or RNA isolation reagent (Ultraspec, Biotecx Laboratories, Houston, TX, USA). To remove potentially contaminating DNA, all the RNA samples were digested with DNase. Fifty micrograms of RNA were mixed with 4 units of RNase-free DNase I (RQ1; Promega, Madison, WI, USA), 50 mm Tris pH 7.5, 10 mm MgCl 2 in 200 l reaction, incubated at 37°C for 30 min. DNase-treated RNA was reverse transcribed. Two micrograms of RNA were incubated with 1 l of oligo(dT) in 20 l reaction, incubated at 100°C for 2 min and stored on ice. Ten microliters of the reaction were reverse transcribed in the presence of reverse transcriptase (RT) buffer (Enzyme Biotechnologies, Cambridge, UK), 1 mm dNTPs, 0.5 l (28 900 U/ml) RNA guard (Pharmacia), 1 l (21 U/l) RT (Enzyme Biotechnologies) in 20 l reaction, incubated at 37°C for 90 min and stored at −20°C before PCR. Control reactions lacking RT were performed to confirm that contaminating DNA was eliminated by DNase treatment.
For semiquantitative RT-PCR, three two-fold (Tat) and four four-fold (␤-actin) diluted cDNA samples were amplified. A 50 l reaction mixture containing 1 l cDNA, 10 l PCR buffer (Tris-HCl 300 mm, NH 4 SO 4 75 mm, MgCl 2 17.5 mm, pH 9.5) for Tat primers or 5 l 
HIV-1 challenge
Control and stably transfected CEM cells were grown without puromycin at least 3 days before infection. The cells were challenged at 5 × 10 5 cell/ml with HIV-1 IIIB/LAI viral doses from 50 to 1000 TCID 50 /ml (MOI from 0.0001 to 0.002) for 24 h at 37°C. Cells were washed, resuspended in fresh medium and incubated in triplicate in 12-well plates (1 ml per well). Cell-free supernatants were collected every 3-4 days and tested for the presence of RT activity or the presence of HIV-1 p24 core protein using a commercial ELISA (Dupont, Boston, MA, USA). At the time of sample collection, cells were counted and replated in fresh medium at 5 × 10 5 cell/ml.
